ArticleEndocrine2016

Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.

Soeren Latteyer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.